• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
188485 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
7 F* |( O' ]: _5 [" K( {
. _7 p  L2 ^* f1 A3 V* P8 _* A" g, P
" ]1 p/ m; B2 Z0 ?4 i4 T; }- u9 MSub-category:
* z% n- _/ I# M+ m$ W" EMolecular Targets + w7 {6 B0 k1 }% q/ p4 {# R

/ {( j7 t2 T* h+ X1 t3 |/ q
5 S- j9 @$ ?3 Y+ P1 ~Category:
6 u# e3 u6 p# h& R9 e- a2 STumor Biology ) x/ C, w0 P: U( X
, {5 q1 F/ w8 s2 I: n- W3 M
% ?0 r. E" w1 n2 N
Meeting:, f" D& E- H, U
2011 ASCO Annual Meeting
2 `- x2 r6 x7 u( F6 e0 s$ \* C, ?  _/ H/ \
3 k! L( `! ~+ `, f+ w% T
Session Type and Session Title:
5 j# Q  k7 T( kPoster Discussion Session, Tumor Biology 6 _9 x: z2 W" X) m6 \* a3 ]. a- R  t

3 G% T0 w6 L3 F8 Q3 A! h8 l2 U  F+ ]! _9 }
Abstract No:
  K2 n2 V" a6 p6 F10517
3 O) S& J( e4 G. t
  X3 S! c! B- s" ?4 _1 J6 w2 n, b  c8 j. y3 r' h
Citation:
! f$ o1 y& B. |, j8 E+ x# UJ Clin Oncol 29: 2011 (suppl; abstr 10517) 3 I) O: C1 c' v( i
$ P0 M% q" E4 `7 A  X! J& I
, M" g% D9 e! ?- R& A& ~
Author(s):& o% _+ J, ]5 P) I
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
! k5 W6 j2 ~5 ]& y
+ b; X( ?9 r4 m! ]1 q3 z. F) C6 g: y4 @5 H* g7 A, ~" w. l0 s8 N
3 \! o/ B' {; p2 A: w, }. G( A
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.6 l" ~8 T8 v5 `# Q

0 B, B" c2 Q( N9 F( uAbstract Disclosures) A( K1 i# @7 h2 h/ v- O$ B$ W* D
2 d/ Y2 n" \) X' f
Abstract:
/ ~( t/ A  q# m3 N3 w4 y
+ a* ~" m: X8 g% x4 F# L; Z
  W1 D. I- ~) @( ?8 ^6 MBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; d  ^+ }! O  S8 [
8 A+ u/ g; s+ H( c9 l) }

9 \9 O( _1 h: z4 E
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 ) _4 f) e5 F) ?
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
5 ?6 n' j  J" D  S; @: P' [% `* {
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 + F* R! P: q4 S# a8 S3 R  X
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。& T2 C. O2 |, [# T
ALK一个指标医院要900多 ...
' |3 I$ c' @- m
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
3 N' R$ [  W- z" ?- r+ P3 ^
( Y( q* }; g: J  E, y1 t现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表